Details for Patent: 9,566,289

Title:	Boron-containing small molecules
Abstract:	This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Inventor(s):	Baker; Stephen J. (Collegeville, PA), Akama; Tsutomu (Sunnyvale, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA), Fieldson; Gregory T. (Morgantown, WV), Leyden; James J. (Malvern, CA)
Assignee:	Anacor Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:	Feb 17, 2016
Application Number:	15/046,322
Claims:	1. A pharmaceutical formulation, comprising: 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable topical carrier. 2. The pharmaceutical formulation of claim 1, wherein the pharmaceutically acceptable topical carrier comprises one or more members selected from polymers, thickeners, buffers, neutralizers, chelating agents, preservatives, surfactants or emulsifiers, antioxidants, waxes or oils, emollients, sunscreens, and a solvent or mixed solvent system. 3. The pharmaceutical formulation of claim 1, wherein the pharmaceutically acceptable topical carrier comprises a solvent system and a chelating agent; wherein the solvent system comprises ethanol and propylene glycol; and wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical formulation, comprising: 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof; a solvent system and a chelating agent. 5. The pharmaceutical formulation of claim 4, wherein the solvent system comprises ethanol. 6. The pharmaceutical formulation of claim 4, wherein the solvent system consists of ethanol. 7. The pharmaceutical formulation of claim 4, wherein the solvent system comprises ethanol and propylene glycol. 8. The pharmaceutical formulation of claim 4, wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical formulation of claim 8, wherein the ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof, is present in a concentration of from about 0.005% to about 2.0% w/w. 10. The pharmaceutical formulation of claim 4, wherein the 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof, is present in a concentration of about 5% w/w. 11. The pharmaceutical formulation of claim 4, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to Trichophyton rubrum or Trichophyton mentagrophytes by topical application of the formulation to the toenail. 12. A pharmaceutical formulation, comprising: about 5% w/w 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof; propylene glycol; ethanol; and ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof. 13. The pharmaceutical formulation of claim 12, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to Trichophyton rubrum or Trichophyton mentagrophytes by topical application of the formulation to the toenail. 14. The pharmaceutical formulation of claim 12, wherein the ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof, is present in a concentration of from about 0.005% to about 2.0% w/w. 15. The pharmaceutical formulation of claim 14, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to Trichophyton rubrum or Trichophyton mentagrophytes by topical application of the formulation to the toenail.